ALLSCHWIL, SWITZERLAND - 27 August 2015 - Actelion Ltd (ATLN.VX) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi^®) will be shared during a `best poster session` at the European Society of Cardiology (ESC) Congress in London, UK.

The poster presentation, titled `Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study` will be part of the `Best posters in pulmonary hypertension treatment strategies` session with a focussed discussion with the lead author, Prof Dr Irene Lang from the Medical University of Vienna, Vienna, Austria, at 15.30 on 30 August. The abstract can be found online.

The ESC Congress will also see the presentation of further information on macitentan (Opsumit^®), with a poster titled `Lack of pharmacokinetic interaction between the dual endothelin receptor antagonist macitentan and the combined oral contraceptive, norethisterone and ethinyl estradiol`. The poster will be available for viewing from 14:00 on 30 August. The abstract can be found online.

###

Notes to Editor:

SELEXIPAG AT ESC-15
Best Poster Presentation:
Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) receiving one, two or no PAH therapies at baseline: results from the GRIPHON study [P2365]
I.M. Lang. S. Gaine, N. Galiè, H.-A. Ghofrani, F.-O Le Brun, V. McLaughlin, L.J. Rubin, G. Simonneau, O. Sitbon, M.M. Hoeper on behalf of the GRIPHON Steering Committee. Sunday, August 30, 15:30 - 16:30

MACITENTAN AT ESC-15
Poster presentation:
Lack of pharmacokinetic interaction between the dual endothelin receptor antagonist macitentan and the combined oral contraceptive, norethisterone and ethinyl estradiol [P2645]
N. Hurst. Sunday, August 30, 14:00 - 18:00

ACTELION LTD
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.